DiaSorin (OTCMKTS:DSRLF) Sees Strong Trading Volume – What’s Next?

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) saw unusually-high trading volume on Thursday . Approximately 300 shares were traded during mid-day trading, an increase of 148% from the previous session’s volume of 121 shares.The stock last traded at $85.78 and had previously closed at $73.85.

Wall Street Analyst Weigh In

DSRLF has been the subject of a number of research analyst reports. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Finally, Zacks Research raised shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold”.

DiaSorin Stock Performance

The stock’s 50 day moving average is $69.53 and its two-hundred day moving average is $74.64.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.